RESEARCH TRIANGLE PARK – GeneCentric Therapeutics has raised $4.5 million in equity from one investor, according to an SEC filing.

And the company could raise up to $3 million more, according to the filing.

In 2019, the company acquired another Triangle-area company that was spun out of the University of North Carolina at Chapel Hill, in a deal reported by WRAL TechWire that intended to enable the combined company to “develop diagnostics tests and more personalized drugs for cancer patients.”

According to the company’s website, it is “building a pipeline of universal cancer subtypes/response signatures across areas of target biology and for the most prevalent and complex cancers with high unmet medical need.”

Precision cancer drug startup GeneCentric acquires nearby Select ImmunoGenomics

The filing was signed by president and CEO of GeneCentric, Michael V. Milburn.

The company raised $1.2 million in debt from four investors earlier this year.